



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

Dr. JOHN YOO JOINS BIOMARK ADVISORY TEAM

Vancouver, British Columbia – (November 17th, 2014) –BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) is pleased to announce that it has appointed Dr. John Yoo to its clinical advisory team.

Dr. Yoo is the Professor and Chair, City-Wide Chief, Department of Otolaryngology-Head and Neck Surgery and Professor in the Department of Oncology at the Schulich School of Medicine & Dentistry, Western University; Director of the Head and Neck Oncology & Reconstructive Surgery Program; and the Co-Chair CancerCare Ontario Head and Neck Disease Site Group.

Rashid Ahmed, President and CEO, comments: “We are extremely excited to welcome Dr. Yoo’s stature into our company. His achievements in the oncology space will be a major asset to BioMark’s group. Dr. Yoo’s clinical expertise and research experience brings depth and practicality as we position our technology for the patient care setting.”

“Biological markers are urgently needed to improve early detection, diagnosis and measuring response to treatment of lung tumours. BioMark’s technology could be a critically important tool for clinicians,” says Dr. Yoo.

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca.

For further information on BioMark, please Contact:

Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-282-6567
Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.